IGF1R and non-small cell lung carcinoma: Figitumumab, which targets IGF-1R, initially exhibited promising efficacy against advanced NSCLC in a phase II study [9], but failed to exhibit safety and efficacy in a phase III trial, and further clinical development was stopped [10].